AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 17- Open
- $64.13
- 52-wk high
- $68.10
- High
- $64.33
- 52-wk low
- $41.13
- Low
- $63.35
- Prev close
- $64.65
Smart money
Earnings
Reported Jul 30, 2026
Earnings came in 28.3% above what analysts expected.
Financials
Sep 2025 to Jun 2026
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| RevenueTotal revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Cost of what it soldCost of revenue | $3.44B | $4.10B | $3.42B | $3.73B |
| Gross profit | $8.79B | $8.41B | $8.07B | $9.25B |
| What it spent | ||||
| Research and development | $2.53B | $2.59B | $2.65B | $2.96B |
| Sales and adminSelling, general and administrative | $1.79B | $2.18B | $1.62B | $1.83B |
| Other operating costsOperating costs not itemised in the filing's summary | $831.0M | $826.0M | $437.0M | $376.0M |
| Total operating expenses | $5.15B | $5.59B | $4.70B | $5.16B |
| What was left | ||||
| Operating profitOperating income | $3.64B | $2.81B | $3.37B | $4.09B |
| Interest on debtInterest expense | $480.0M | $432.0M | $411.0M | $407.0M |
| Profit before tax | $3.11B | $1.47B | $3.24B | $4.09B |
| TaxIncome tax expense | $919.0M | $384.0M | $561.0M | $770.0M |
| Net profitNet income | $2.20B | $1.09B | $2.68B | $3.32B |
| EBITDAEarnings before interest, tax, depreciation, amortisation | $4.61B | $2.88B | $4.25B | $4.94B |
Technicals
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
56balanced
20D volatility
22%annualized
52-week range
$63.83$41.13$68.10
20D support
News
News
What the news says
50 articles · 7 days
Coverage is bullish
30 bullish · 15 neutral · 5 bearish
Tone of tracked coverage
Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A
NeutralAug 14Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Leans bullishAug 14Vanguard Is "Cautious" on U.S. Growth Stocks. These 2 Value ETFs Could Be Smarter Buys for Long-Term Investors.
Leans bullish
